X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE GSK PHARMA SUVEN LIFE/
GSK PHARMA
 
P/E (TTM) x 19.8 63.8 31.0% View Chart
P/BV x 3.7 10.3 35.8% View Chart
Dividend Yield % 1.0 1.2 82.6%  

Financials

 SUVEN LIFE   GSK PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
GSK PHARMA
Mar-17
SUVEN LIFE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3393,838 8.8%   
Low Rs1442,637 5.5%   
Sales per share (Unadj.) Rs39.2354.2 11.1%  
Earnings per share (Unadj.) Rs7.539.8 18.8%  
Cash flow per share (Unadj.) Rs8.842.9 20.5%  
Dividends per share (Unadj.) Rs2.0030.00 6.7%  
Dividend yield (eoy) %0.80.9 89.4%  
Book value per share (Unadj.) Rs49.0236.9 20.7%  
Shares outstanding (eoy) m127.2884.70 150.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.29.1 67.3%   
Avg P/E ratio x32.481.4 39.7%  
P/CF ratio (eoy) x27.575.5 36.4%  
Price / Book Value ratio x4.913.7 36.1%  
Dividend payout %26.875.4 35.5%   
Avg Mkt Cap Rs m30,732274,216 11.2%   
No. of employees `0001.04.7 20.3%   
Total wages/salary Rs m4164,830 8.6%   
Avg. sales/employee Rs Th5,236.16,387.0 82.0%   
Avg. wages/employee Rs Th436.51,028.3 42.4%   
Avg. net profit/employee Rs Th995.5717.1 138.8%   
INCOME DATA
Net Sales Rs m4,99530,000 16.7%  
Other income Rs m194728 26.6%   
Total revenues Rs m5,18930,728 16.9%   
Gross profit Rs m1,2334,190 29.4%  
Depreciation Rs m167263 63.6%   
Interest Rs m540-   
Profit before tax Rs m1,2054,655 25.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m2551,744 14.6%   
Profit after tax Rs m9503,368 28.2%  
Gross profit margin %24.714.0 176.7%  
Effective tax rate %21.237.5 56.5%   
Net profit margin %19.011.2 169.3%  
BALANCE SHEET DATA
Current assets Rs m4,98616,742 29.8%   
Current liabilities Rs m1,0427,202 14.5%   
Net working cap to sales %79.031.8 248.3%  
Current ratio x4.82.3 205.8%  
Inventory Days Days6152 117.7%  
Debtors Days Days3921 188.3%  
Net fixed assets Rs m3,1268,635 36.2%   
Share capital Rs m127847 15.0%   
"Free" reserves Rs m3,71719,222 19.3%   
Net worth Rs m6,23620,069 31.1%   
Long term debt Rs m43210 4,323.0%   
Total assets Rs m8,07930,038 26.9%  
Interest coverage x23.2NM-  
Debt to equity ratio x0.10 13,911.3%  
Sales to assets ratio x0.61.0 61.9%   
Return on assets %12.411.2 110.8%  
Return on equity %15.216.8 90.7%  
Return on capital %18.925.5 74.1%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,666528 883.8%   
Fx outflow Rs m9427,193 13.1%   
Net fx Rs m3,724-6,665 -55.9%   
CASH FLOW
From Operations Rs m9222,360 39.1%  
From Investments Rs m-6193,008 -20.6%  
From Financial Activity Rs m-698-5,108 13.7%  
Net Cashflow Rs m-396260 -152.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 102,036 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 16, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS